| Literature DB >> 11166863 |
M Parliament1, N Jha, E Rapp, C Smith, J MacKinnon, J M Nabholtz, J Hanson, T Reiman, J Mackey.
Abstract
We report a phase I/II study of weekly concurrent carboplatin and radiotherapy in patients with nasopharyngeal carcinoma (M0 stage). Of 47 patients registered, 45 completed the treatment course. Twenty-six (55%) (95% CI, 41-69%) patients experienced > or =grade 3 acute toxicity (RTOG). Five (11%) (95% CI, 2-20%) patients experienced > or =grade 3 chronic toxicity. This regimen appears to have acceptable toxicity compared to the experimental arm of Phase III Intergroup Study 0099, but progression-free and overall survival are probably inferior. At present, there is no data to suggest that carboplatin can replace cisplatin for concurrent chemoradiation for NPC.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11166863 DOI： 10.1016/s0167-8140(00)00330-3
Source DB: PubMed Journal: Radiother Oncol ISSN： 0167-8140 Impact factor: 6.280